ATLANTA, Aug 19, 2009 (UPI via COMTEX) -- A human papillomavirus vaccine
analysis found adverse events consistent with pre-licensing data except for
fainting and blood clots, U.S. researchers say.
In 2006, the Food and Drug Administration licensed the quadrivalent human
papillomavirus vaccine for females ages 9-26 to prevent infection with genital
human papillomavirus types 6, 11, 16 and 18.
Dr. Barbara A. Slade of the Centers for Disease Control and Prevention in
Atlanta and colleagues analyzed reports of adverse events following qHPV
immunization received by the U.S. Vaccine Adverse Event Reporting System.
During the study period, the system received 12,424 reports of adverse events
following immunization with qHPV -- an overall reporting rate of 53.9 reports
per 100,000 vaccine doses distributed.
The analysis, published in the Journal of the Americans Medical Association,
found that among the 12,424 adverse events, 772, or 6.2 percent, were serious,
including 32 reports of death.
"The post-licensure safety profile presented here is broadly consistent with
safety data from pre-licensure trials," the study authors said.
URL: www.upi.com
Copyright 2009 by United Press International